Evaluation of cardiac activity and pharmacokinetic analysis of 3H-adriamycin in patients pretreated with beta-methyldigoxin.
The consequences at the cardiac level of adriamycin treatment alone or in association with the cardiac glycoside beta-methyldigoxin, were evaluated with reference to the PEP/LVET ratio, heart rate, and minimum blood pressure. The variation usually seen in the PEP/LVET ratio when adriamycin is administered alone was not observed when pretreatment with beta-methyldigoxin was also given. A similar situation is found with variations in blood pressure and heart rate. From a pharmacokinetic point of view, this treatment scheme does not seem to affect the general behavior of the antibiotic.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004077:Digoxin / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000378:metabolism / Q000494:pharmacology*; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008520:Medigoxin / Q000494:pharmacology*; D008875:Middle Aged; D008954:Models, Biological
D004077:Digoxin; D004317:Doxorubicin; D008520:Medigoxin